Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Decibel Bio Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, BYRNES, DAVID R, who is the busiest examiner with 1 busiest examiner pending action. The filing is located within 1 distinct art unit, representing a point of contact for the company's current prosecution efforts. This concentration in 1 distinct art unit within the Biotechnology & Pharmaceuticals field suggests a highly specific technical focus for the active matter.
With only 1 pending office action, the portfolio's immediate progress is tied to the 1 distinct examiner identified. Practitioners should focus on the specific precedents of the 1 distinct art unit to navigate this case effectively. The presence of 1 busiest examiner pending action under BYRNES, DAVID R means that current feedback originates from this official. This narrow scope allows for a targeted response strategy without the complexity of managing multiple examiners or art units. The 1 pending office action represents the entirety of the company's current engagement in this technology area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BYRNES, DAVID R | 1 | 78.2% | +20.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18969763 | PROGRAMMABLE EPIGENETIC CONTROL OF GENE EXPRESSION IN PLANTS | BYRNES, DAVID R | — |
| Art Unit | Apps |
|---|---|
| 1662 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18969763 | PROGRAMMABLE EPIGENETIC CONTROL OF GENE EXPRESSION IN PLANTS | BYRNES, DAVID R | 1662 | §112DP | Non-Final OA | — | Pending | Dec 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDecibel Bio Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
David R Byrnes has the most, with 1 of Decibel Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
